Drug profile · INN
trametinib dimethyl sulfoxide
MEKINIST INITIAL APPROVAL
trametinib dimethyl sulfoxide (MEKINIST INITIAL APPROVAL) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — trametinib dimethyl sulfoxide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 10
- Data quality
- 0.84
Quick answer
trametinib dimethyl sulfoxide (MEKINIST INITIAL APPROVAL) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trametinib dimethyl sulfoxide?
trametinib dimethyl sulfoxide (MEKINIST INITIAL APPROVAL) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for trametinib dimethyl sulfoxide?
MEKINIST INITIAL APPROVAL is a marketed brand name for trametinib dimethyl sulfoxide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trametinib dimethyl sulfoxide?
trametinib dimethyl sulfoxide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.